Biontech fights for survival as layoffs loom and Bayer nears glyphosate deal

Biontech, once hailed as Germany’s biotech champion, is now fighting for survival as mass layoffs loom and investor confidence wanes. On Friday, the Mainz-based company confirmed internal sources that hundreds of jobs are at risk, with executives and investors engaged in urgent restructuring talks to salvage the firm after years of declining revenues and failed diversification.
The crisis at Biontech, which rose to prominence during the COVID-19 pandemic with its mRNA vaccine developed alongside Pfizer, reflects broader challenges in Europe’s biotech sector. Once valued at over €40 billion, the company’s market capitalisation has plummeted, and its pipeline of new drugs has underperformed. Employees, speaking anonymously to *Handelsblatt*, describe a company in disarray, with morale at an all-time low as management explores cost-cutting measures and potential asset sales.
Meanwhile, Bayer is on the verge of resolving its long-running glyphosate litigation nightmare. After the 2018 acquisition of Monsanto saddled the German conglomerate with tens of thousands of lawsuits and billions in damages, Bayer has now reached a tentative agreement with plaintiffs’ lawyers to settle the majority of remaining claims. The deal, expected to close within weeks, would cap Bayer’s legal exposure at around $10 billion—a fraction of the $16 billion it had previously set aside—marking a rare victory for the embattled group.
In a contrasting move, German industrial giant Renk has expanded its defence footprint by acquiring UK-based David Brown Defence for $200 million, securing a key supplier of armoured vehicle transmissions. The deal underscores Europe’s accelerating rearmament efforts amid geopolitical tensions, with Renk positioning itself as a critical link in NATO’s supply chains.
Switzerland’s corporate resilience was further highlighted as four of its firms—Roche, Novartis, Nestlé, and ABB—ranked among the world’s top 100 most valuable companies in the first half of 2026. Their combined market capitalisation surged by 18% in six months, reaching $61.9 trillion, with US tech giants still dominating the rankings. The data, released by EY, signals Europe’s gradual recovery in global market share, though its presence remains half what it was two decades ago.
Elsewhere, Continental’s automotive components unit Contitech is reportedly on the block, with private equity firm LoneStar in advanced talks to acquire the division for over €1 billion. The sale, if completed, would mark another major exit by a German industrial group from non-core assets.
As Europe’s corporate landscape shifts, the contrast between struggling legacy firms and resilient multinationals underscores the continent’s uneven economic recovery. For Biontech, the coming months will determine whether it can regain its footing—or fade into the annals of once-great German innovators.
Follow us for live European news
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
2 further sources not geolocated




:format(jpg)/f.elconfidencial.com%2Foriginal%2F7ba%2F72f%2F48a%2F7ba72f48a5dfcc49ee50d5fb866a9965.jpg)






